Annual CFO
-$1.39 M
+$3.74 M+72.94%
June 30, 2024
Summary
- As of February 8, 2025, AYTU annual cash flow from operations is -$1.39 million, with the most recent change of +$3.74 million (+72.94%) on June 30, 2024.
- During the last 3 years, AYTU annual CFO has risen by +$24.58 million (+94.65%).
- AYTU annual CFO is now -4874.91% below its all-time high of -$27.90 thousand, reached on August 31, 2007.
Performance
AYTU Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.19 M
-$402.00 K-51.02%
September 30, 2024
Summary
- As of February 8, 2025, AYTU quarterly cash flow from operations is -$1.19 million, with the most recent change of -$402.00 thousand (-51.02%) on September 30, 2024.
- Over the past year, AYTU quarterly CFO has dropped by -$979.00 thousand (-463.98%).
- AYTU quarterly CFO is now -112.71% below its all-time high of $9.37 million, reached on June 30, 2023.
Performance
AYTU Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$2.37 M
-$979.00 K-70.53%
September 30, 2024
Summary
- As of February 8, 2025, AYTU TTM cash flow from operations is -$2.37 million, with the most recent change of -$979.00 thousand (-70.53%) on September 30, 2024.
- Over the past year, AYTU TTM CFO has dropped by -$6.17 million (-162.16%).
- AYTU TTM CFO is now -127.01% below its all-time high of $8.77 million, reached on March 31, 2024.
Performance
AYTU TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AYTU Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +72.9% | -464.0% | -162.2% |
3 y3 years | +94.7% | +68.6% | +89.1% |
5 y5 years | +90.0% | +86.5% | +91.4% |
AYTU Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +95.2% | -112.7% | +87.0% | -127.0% | +93.1% |
5 y | 5-year | at high | +95.2% | -112.7% | +89.7% | -127.0% | +93.1% |
alltime | all time | -4874.9% | +95.2% | -112.7% | +89.7% | -127.0% | +93.1% |
Aytu BioPharma Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$1.19 M(+51.0%) | -$2.37 M(+70.5%) |
Jun 2024 | -$1.39 M(-72.9%) | -$788.00 K(+210.2%) | -$1.39 M(-115.8%) |
Mar 2024 | - | -$254.00 K(+88.1%) | $8.77 M(+43.4%) |
Dec 2023 | - | -$135.00 K(-36.0%) | $6.11 M(+60.5%) |
Sep 2023 | - | -$211.00 K(-102.3%) | $3.81 M(-174.2%) |
Jun 2023 | -$5.13 M(-82.2%) | $9.37 M(-422.3%) | -$5.13 M(-76.2%) |
Mar 2023 | - | -$2.91 M(+19.1%) | -$21.59 M(-22.3%) |
Dec 2022 | - | -$2.44 M(-73.3%) | -$27.80 M(-18.7%) |
Sep 2022 | - | -$9.15 M(+28.9%) | -$34.18 M(+18.6%) |
Jun 2022 | -$28.82 M(+11.0%) | -$7.09 M(-22.2%) | -$28.82 M(+2.9%) |
Mar 2022 | - | -$9.12 M(+3.3%) | -$28.00 M(+1.2%) |
Dec 2021 | - | -$8.82 M(+132.7%) | -$27.67 M(+27.1%) |
Sep 2021 | - | -$3.79 M(-39.6%) | -$21.77 M(-16.1%) |
Jun 2021 | -$25.96 M(-8.5%) | -$6.28 M(-28.5%) | -$25.96 M(-5.4%) |
Mar 2021 | - | -$8.78 M(+200.3%) | -$27.45 M(-9.1%) |
Dec 2020 | - | -$2.92 M(-63.4%) | -$30.19 M(-9.5%) |
Sep 2020 | - | -$7.98 M(+2.8%) | -$33.37 M(+17.6%) |
Jun 2020 | -$28.37 M(+105.1%) | -$7.76 M(-32.6%) | -$28.37 M(+17.8%) |
Mar 2020 | - | -$11.52 M(+88.9%) | -$24.08 M(+51.7%) |
Dec 2019 | - | -$6.10 M(+104.1%) | -$15.87 M(+12.8%) |
Sep 2019 | - | -$2.99 M(-14.0%) | -$14.07 M(+1.8%) |
Jun 2019 | -$13.83 M(-13.2%) | -$3.47 M(+4.9%) | -$13.83 M(-7.2%) |
Mar 2019 | - | -$3.31 M(-23.1%) | -$14.90 M(-4.9%) |
Dec 2018 | - | -$4.30 M(+56.8%) | -$15.67 M(+8.3%) |
Sep 2018 | - | -$2.74 M(-39.6%) | -$14.47 M(-9.2%) |
Jun 2018 | -$15.94 M(+15.3%) | -$4.54 M(+11.4%) | -$15.94 M(+8.7%) |
Mar 2018 | - | -$4.08 M(+31.5%) | -$14.67 M(+13.0%) |
Dec 2017 | - | -$3.10 M(-26.5%) | -$12.98 M(+2.1%) |
Sep 2017 | - | -$4.22 M(+29.0%) | -$12.71 M(-8.1%) |
Jun 2017 | -$13.83 M(+29.8%) | -$3.27 M(+36.6%) | -$13.83 M(+4.6%) |
Mar 2017 | - | -$2.39 M(-15.7%) | -$13.23 M(+0.1%) |
Dec 2016 | - | -$2.84 M(-46.8%) | -$13.22 M(-4.4%) |
Sep 2016 | - | -$5.33 M(+100.1%) | -$13.83 M(+29.8%) |
Jun 2016 | -$10.66 M | -$2.66 M(+11.7%) | -$10.66 M(+33.3%) |
Mar 2016 | - | -$2.39 M(-30.9%) | -$7.99 M(+42.5%) |
Dec 2015 | - | -$3.45 M(+59.9%) | -$5.61 M(+157.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2015 | - | -$2.16 M(>+9900.0%) | -$2.18 M(+4618.4%) |
Jun 2015 | -$6.63 M(>+9900.0%) | - | - |
Feb 2015 | - | -$13.40 K(+44.1%) | -$46.20 K(+12.4%) |
Nov 2014 | - | -$9300.00(+2.2%) | -$41.10 K(+6.2%) |
Aug 2014 | -$38.70 K(-99.3%) | -$9100.00(-36.8%) | -$38.70 K(+11.2%) |
Jun 2014 | -$5.50 M(>+9900.0%) | - | - |
May 2014 | - | -$14.40 K(+73.5%) | -$34.80 K(-2.5%) |
Feb 2014 | - | -$8300.00(+20.3%) | -$35.70 K(0.0%) |
Nov 2013 | - | -$6900.00(+32.7%) | -$35.70 K(-5.3%) |
Aug 2013 | -$37.70 K(-0.3%) | -$5200.00(-66.0%) | -$37.70 K(-16.4%) |
May 2013 | - | -$15.30 K(+84.3%) | -$45.10 K(+26.3%) |
Feb 2013 | - | -$8300.00(-6.7%) | -$35.70 K(-0.3%) |
Nov 2012 | - | -$8900.00(-29.4%) | -$35.80 K(-5.5%) |
Aug 2012 | -$37.80 K(-41.7%) | -$12.60 K(+113.6%) | -$37.90 K(+9.5%) |
May 2012 | - | -$5900.00(-29.8%) | -$34.60 K(-25.1%) |
Feb 2012 | - | -$8400.00(-23.6%) | -$46.20 K(-27.7%) |
Nov 2011 | - | -$11.00 K(+18.3%) | -$63.90 K(-1.4%) |
Aug 2011 | -$64.80 K(+49.3%) | -$9300.00(-46.9%) | -$64.80 K(-0.5%) |
May 2011 | - | -$17.50 K(-33.0%) | -$65.10 K(+7.8%) |
Feb 2011 | - | -$26.10 K(+119.3%) | -$60.40 K(+36.7%) |
Nov 2010 | - | -$11.90 K(+24.0%) | -$44.20 K(+1.8%) |
Aug 2010 | -$43.40 K(-6.9%) | -$9600.00(-25.0%) | -$43.40 K(+7.2%) |
May 2010 | - | -$12.80 K(+29.3%) | -$40.50 K(+14.7%) |
Feb 2010 | - | -$9900.00(-10.8%) | -$35.30 K(-4.3%) |
Nov 2009 | - | -$11.10 K(+65.7%) | -$36.90 K(-21.0%) |
Aug 2009 | -$46.60 K(+4.0%) | -$6700.00(-11.8%) | -$46.70 K(-6.0%) |
May 2009 | - | -$7600.00(-33.9%) | -$49.70 K(-10.9%) |
Feb 2009 | - | -$11.50 K(-45.0%) | -$55.80 K(+0.7%) |
Nov 2008 | - | -$20.90 K(+115.5%) | -$55.40 K(+23.4%) |
Aug 2008 | -$44.80 K(+60.6%) | -$9700.00(-29.2%) | -$44.90 K(+8.7%) |
May 2008 | - | -$13.70 K(+23.4%) | -$41.30 K(+4.8%) |
Feb 2008 | - | -$11.10 K(+6.7%) | -$39.40 K(+13.5%) |
Nov 2007 | - | -$10.40 K(+70.5%) | -$34.70 K(+24.4%) |
Aug 2007 | -$27.90 K | -$6100.00(-48.3%) | -$27.90 K(+28.0%) |
May 2007 | - | -$11.80 K(+84.4%) | -$21.80 K(+118.0%) |
Feb 2007 | - | -$6400.00(+77.8%) | -$10.00 K(+177.8%) |
Nov 2006 | - | -$3600.00 | -$3600.00 |
FAQ
- What is Aytu BioPharma annual cash flow from operations?
- What is the all time high annual CFO for Aytu BioPharma?
- What is Aytu BioPharma annual CFO year-on-year change?
- What is Aytu BioPharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aytu BioPharma?
- What is Aytu BioPharma quarterly CFO year-on-year change?
- What is Aytu BioPharma TTM cash flow from operations?
- What is the all time high TTM CFO for Aytu BioPharma?
- What is Aytu BioPharma TTM CFO year-on-year change?
What is Aytu BioPharma annual cash flow from operations?
The current annual CFO of AYTU is -$1.39 M
What is the all time high annual CFO for Aytu BioPharma?
Aytu BioPharma all-time high annual cash flow from operations is -$27.90 K
What is Aytu BioPharma annual CFO year-on-year change?
Over the past year, AYTU annual cash flow from operations has changed by +$3.74 M (+72.94%)
What is Aytu BioPharma quarterly cash flow from operations?
The current quarterly CFO of AYTU is -$1.19 M
What is the all time high quarterly CFO for Aytu BioPharma?
Aytu BioPharma all-time high quarterly cash flow from operations is $9.37 M
What is Aytu BioPharma quarterly CFO year-on-year change?
Over the past year, AYTU quarterly cash flow from operations has changed by -$979.00 K (-463.98%)
What is Aytu BioPharma TTM cash flow from operations?
The current TTM CFO of AYTU is -$2.37 M
What is the all time high TTM CFO for Aytu BioPharma?
Aytu BioPharma all-time high TTM cash flow from operations is $8.77 M
What is Aytu BioPharma TTM CFO year-on-year change?
Over the past year, AYTU TTM cash flow from operations has changed by -$6.17 M (-162.16%)